CareDx Inc

CDNA remains in a Stage 2 advancing uptrend with rising EMAs and higher highs. After an overbought rally, price has pulled back into the rising 9/20 EMA support zone and is tightly tracking without fresh momentum. Medium-term bias stays bullish, but short-term timing lacks a clear edge. Defer new entry and stalk for pullback acceptance into the 9/20 EMA area, participating on continuation once support holds.

• ↑Q2 revenue rose 52% YoY to $132M, driven by 61% testing revenue growth
• ↑Raised full-year guidance to $490–$500M, reflecting sustained demand
• ↓Proposed LCD changes could slash ~$15M revenue if finalized